PROPRIETARY PIPELINE
A focused pipeline.
One programmable-immunity strategy.
Byterna is advancing in vivo CAR-T, in vivo immunomodulation and personalized neoantigen cancer vaccines through a shared foundation of AI-enabled design, circular mRNA, analytics and integrated CMC and manufacturing. BR101 has a registered investigator-initiated trial in relapsed/refractory multiple myeloma (NCT07537049). Autoimmune diseases are presented separately as a preclinical development setting.
Two therapeutic directions. One shared development system.
PORTFOLIO
Programs from
preclinical development to a registered IIT.
| Program | Disease setting | Product design | Current status |
|---|---|---|---|
BR101Target: BCMA/CD19 | Disease settingRelapsed/refractory multiple myeloma | Product designIn Vivo CAR-T | |
| Disease settingAutoimmune diseases | Product designIn Vivo CAR-T | Current statusPreclinical | |
BR102Target: Undisclosed | Disease settingAutoimmune diseases | Product designIn Vivo CAR-T | Current statusPreclinical |
BR103Target: Undisclosed | Disease settingSolid Tumors | Product designIn Vivo CAR-T | Current statusPreclinical |
BR201Target: Undisclosed | Disease settingSolid Tumors | Product designIn Vivo Immunomodulator | Current statusPreclinical |
BR202Target: Patient-specific neoantigens | Disease settingPersonalized oncology | Product designPersonalized cancer vaccine | Current statusPreclinical |
BR101 · Lead in vivo CAR-T program
A dual-target program with a registered investigator-initiated trial.
BR101 is a BCMA/CD19 circular mRNA program designed for transient, non-integrating immune-cell programming in vivo. It is being evaluated in a registered investigator-initiated trial in relapsed/refractory multiple myeloma (NCT07537049).
- Target
- BCMA/CD19
- Disease setting
- Relapsed/refractory multiple myeloma
- Product design
- In Vivo CAR-T
- Current status
- IIT
- Registry record
- NCT07537049
BR202 · Strategic personalized cancer vaccine program
From tumor profile to a manufacturable vaccine design.
BR202 is an AI-native personalized cancer vaccine program. NeoDiscovery.AI predicts, ranks and optimizes multi-neoantigen combinations from each patient's tumor data. The selected antigen set informs circular mRNA construct design, while process and quality data establish a traceable path toward individualized manufacturing and release.
Explore NeoDiscovery.AI ↗